Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
AN INSULIN pill, long desired by diabetes doctors and patients but abandoned as not physically viable, could be available by the end of this decade as a tiny Israeli company races a Danish pharmaceutical giant to be first with what could be a multibillion-dollar product.
In the pharmaceutical industry?s equivalent of a David and Goliath story, the companies at the forefront are Novo Nordisk, the world?s largest seller of insulin products with a market value of about $74bn, and Oramed Pharmaceuticals, with a market value of only $50m and headquartered in Jerusalem, where the biblical David held court.
http://www.bdlive.co.za/life/health/2013/10/10/david-and-goliath-in-race-for-insulin-pill
In the pharmaceutical industry?s equivalent of a David and Goliath story, the companies at the forefront are Novo Nordisk, the world?s largest seller of insulin products with a market value of about $74bn, and Oramed Pharmaceuticals, with a market value of only $50m and headquartered in Jerusalem, where the biblical David held court.
http://www.bdlive.co.za/life/health/2013/10/10/david-and-goliath-in-race-for-insulin-pill